8 October 2026
originally posted on LinkedIn.
By Giulia Segafredo Senior Access Manager, Non-Communicable Diseases, Medicines Patent Pool(MPP)
At the World Cancer Congress 2026 in Hong Kong, I had the opportunity to join oncologists, patient advocates, healthcare providers and global health partners in discussions about one of the most pressing challenges in cancer care: how do we ensure that medical innovation reaches the people who need it, wherever they live?
The conversations reinforced an important lesson: innovation alone does not deliver access.
Oncology is among the most rapidly evolving areas of medicine today. Innovations such as highly targeted therapies, antibody-drug conjugates, and cell therapies are transforming the way cancer is treated. And these scientific advances have transformed the outlook for many cancers. Innovative medicines can offer people the prospect of longer and better lives. Yet the public health value of innovation is realised only when patients can be diagnosed, receive the right treatment, and be supported throughout their care journey.
Cancer care illustrates this particularly clearly. Making a medicine available is essential, but it is not the end of the access journey.
Patients need timely and accurate diagnosis and access to appropriate healthcare facilities. Healthcare professionals need the training and resources to provide appropriate care. Hospitals and treatment centres need the infrastructure to deliver and monitor treatment.
Affordability is often at the centre of discussions on access to medicines. However, affordability for individual patients is fundamentally different from affordability from a public health perspective. Sustainable financing and procurement mechanisms are needed so that medicines can be incorporated into care pathways rather than remaining out of reach.
Governments have a central role in creating these conditions. Their decisions on health priorities, benefit packages, procurement, registration, financing and service delivery shape whether an available medicine can be used in practice. The most appropriate approach will differ by country because health-system capacities, infrastructure and constraints vary.
Patient organisations, clinicians and other health organisations are equally important. Their experience helps identify practical barriers, connect people with care and ensure that access strategies respond to what patients and health systems actually need.
Within this broader ecosystem, public health-oriented voluntary licensing can be one useful tool for improving access to certain essential innovative medicines.
Through voluntary licensing, an originator company can authorise selected manufacturers to develop, manufacture and supply quality-assured generic versions of a medicine in an agreed territory, subject to the terms of the licence and relevant regulatory approvals. MPP contributes experience in negotiating and managing such licences, selecting sublicensees and supporting implementation with innovators and manufacturers.
This approach is collaborative by design. It starts with the innovation and commitment of the originator company. It relies on manufacturers investing in product development and regulatory approval. It also depends on governments, health organisations, clinicians, procurement partners and patient communities creating the conditions for appropriate uptake.
For originator companies, working with MPP can provide a structured way to explore how an access strategy for an innovative medicine might be extended to additional countries and patient populations. Voluntary licensing will not be appropriate for every product or context, but where it is suitable, it can complement other access approaches and build on the work already under way in countries.
The experience of nilotinib for chronic myeloid leukaemia, or CML, offers an early illustration of this complementarity.
In 2022, through the Union for International Cancer Control (UICC)-led ATOM Coalition, Novartis and MPP signedthe first public health-oriented voluntary licence for a cancer medicine. The agreement enables selected generic manufacturers to develop, manufacture and supply generic versions of nilotinib in the licensed territory, subject to local regulatory authorisation.
The significance of this experience is not simply that a licence was signed. It is that implementation has shown what must happen after a licence if a medicine is to reach patients. Findings presented at WCC2026 highlighted that regulatory approval and generic availability do not automatically translate into access. Diagnostics, financing, clinical capacity and health-system readiness continue to influence whether people benefit.
They also highlighted the importance of building on existing foundations. In the case of CML, The Max Foundationhas played a major role through its longstanding work in CML care and patient support. The implementation of the nilotinib licence benefited from those foundations. MPP is delighted to support and complement these efforts by contributing a licensing pathway that can help broaden the availability of quality-assured generic nilotinib.
Novartis made the model possible by granting the licence and pioneering a new approach in oncology. Generic manufacturers then invested in developing and securing regulatory approvals for licensed products. Governments, clinicians, patient communities and other partners have each contributed expertise needed to address practical barriers to access.
The lessons extend beyond nilotinib. Continued innovation is vital across cancer and other non-communicable diseases, yet too many people still do not benefit from advances in treatment.
Through its established collaboration with the World Health Organization and other partners, MPP identifies essential innovative medicines for which voluntary licensing could have significant public health impact. This process assesses unmet public health needs, access barriers, product characteristics, country contexts and the wider conditions required for successful use, helping to identify where licensing could most effectively contribute to expanding access.
The experience with nilotinib demonstrates that voluntary licensing can be a valuable complement to the efforts already being undertaken by innovators, governments, healthcare providers, patient organisations and global health partners. It is not a substitute for company-led access strategies, health system investments, procurement initiatives or patient support programmes. Rather, it can help reinforce these efforts and contribute to a continuum of care that supports both broader and more sustainable access to treatment.
We believe there are opportunities to apply these lessons more broadly and look forward to working with originator companies and other partners to explore where public health-oriented voluntary licensing could support access to additional essential innovative medicines. MPP’s role is one part of a much larger ecosystem: contributing expertise in licensing and implementation while working alongside partners whose complementary efforts ultimately determine whether innovation reaches patients and can be sustained over the long term.
I left WCC2026 encouraged by the openness of the discussion and by the shared recognition that access requires partnership. Originator and generic companies, governments, healthcare providers, patient organisations, international partners and access organisations each bring capabilities that others cannot replace.
The opportunity now is to identify where those capabilities can come together around other essential innovative medicines, and to design access approaches that respond to the realities of each disease and country.
Innovation is indispensable. It creates new possibilities for patients and health systems. But those possibilities become meaningful only when the systems surrounding a medicine allow people to benefit.
Innovation alone does not deliver access. Partnership turns innovation into impact.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.